January 28, 2025

New Member: Welcome in our cluster to Akribion Therapeutics GmbH

New Member: Welcome in our cluster to Akribion Therapeutics GmbH
Go back

Akribion Therapeutics is developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion. Its G-dase® E nuclease has the ability to kill cells by shredding DNA and RNA, but only if there is a highly specific match between the guide RNA and an intracellular RNA sequence. This ensures that only the targeted cells are affected, leaving healthy cells unharmed.
Akribion is exploring applications in oncology, autoimmune diseases, fibrosis, and infectious diseases, as the technology can be quickly adapted to target different biomarkers and cells.

If you would like to learn more, please visit their Website.
Looking forward to your active participation!

Our latest News

discover more
Center of Excellence in Oncology: NCT Heidelberg and Mannheim Cancer Center Receive Joint Funding

Center of Excellence in Oncology: NCT Heidelberg and Mannheim Cancer Center Receive Joint Funding

Joint Press Release from NCT Heidelberg and Mannheim University Medical Center The National Center for Tumor Diseases (NCT) Heidelberg and the Mannheim Cancer Center (MCC) are receiving joint funding as a Center of Excellence in Oncology for the first time. German Cancer Aid is providing 4.8 million euros over four years for the new consortium. […]

read more
Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease

Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease

Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease Paris, August 4, 2026. Sanofi today announced that the European Commission (EC) has approved an extension of the indication for MenQuadfi (Meningococcal Group A, C, W and Y conjugate vaccine) to include infants from six weeks of age […]

read more
A new genetic tool helps researchers uncover the logic of gene regulation

A new genetic tool helps researchers uncover the logic of gene regulation

Researchers use synthetic biology approaches to test hundreds of DNA sequences for their effect on regulating gene expression Summary The human genome contains over 20,000 genes. However, at any given time and in a given cell, only a fraction of them are active. Researchers from EMBL Heidelberg’s Krebs Group have come up with an innovative […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp